FINWIRES · TerminalLIVE
FINWIRES

$JNJ

33 stories mentioning JNJ

Every FINWIRES story that references JNJ, newest first.

Insider Trading

Johnson & Johnson Insider Sold Shares Worth $2,411,500, According to a Recent SEC Filing

Kathryn E Wengel, Executive Vice President, Chief Technical Operations & Risk Officer, on June 11, 2026, sold 10,000 shares in Johnson & Johnson (JNJ) for $2,411,500. Following the Form 4 filing with the SEC, Wengel has control over a total of 114,659 common shares of the company, with 114,288 shares held directly and 371 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/200406/000020040626000127/xslF345X05/wk-form4_1781299408.xml

$JNJ
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) fell 1.8%.In corporate news, Prenetics Global (PRE) shares dropped 8.7% after the company reported a Q1 loss of $1.36 per diluted share, widening from the loss of $0.80 a year earlier.Sanofi (SNY) shares fell 2.3%. The company said it will discontinue a phase 3 trial of riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family. Johnson & Johnson shares rose 0.7%.Pfizer's (PFE) recent share decline has pulled its valuation back toward historical levels, easing some of the concerns raised in its earlier outlook, RBC Capital Markets said. Pfizer's stock fell 0.2%.

$JNJ$PFE$PRE$SNY
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.2%.In corporate news, Prenetics Global (PRE) shares dropped 7% after the company reported a Q1 loss of $1.36 per diluted share, wider than a loss of $0.80 a year earlier.Sanofi (SNY) shares fell 2.3%. The firm said it will discontinue a phase 3 trial of riliprubart in patients with a type of chronic inflammatory demyelinating polyneuropathy after an interim review found the study was unlikely to provide sufficient efficacy.Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family. Johnson & Johnson shares were up 0.8%.

$JNJ$PRE$SNY
Wire

Johnson & Johnson Ordered to Pay $32 Million in California Talc Verdict

Johnson & Johnson (JNJ) was ordered by a Los Angeles jury to pay $32 million to the family of a California woman who died from pleural mesothelioma after alleged exposure to asbestos-contaminated talc, according to the law firm representing the family.The case was brought on behalf of Maria Lozano, who died in 2024, and was continued by her three children. The family's law firm, Dean Omar Branham Shirley, said Wednesday in a statement that Lozano regularly used Johnson & Johnson's talc-based baby powder beginning in the early 1970s and argued that the product caused her illness.Johnson & Johnson argued that Lozano's asbestos exposure stemmed from other sources, but the jury rejected those theories, the law firm said.Johnson & Johnson didn't immediately reply to a request for comment from.Price: $239.38, Change: $+2.38, Percent Change: +1.00%

$JNJ
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.

$INCY$JNJ$LLY$TNGX
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$INCY$JNJ$LLY
Johnson & Johnson to Acquire Firefly Bio in $1 Billion Deal
US Markets

Johnson & Johnson to Acquire Firefly Bio in $1 Billion Deal

Johnson & Johnson (JNJ) said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.The acquisition will give the company access to Firefly Bio's proprietary Firelink degrader antibody conjugate platform, which is focused on cancers driven by Kirsten rat sarcoma viral oncogene homolog, or KRAS, mutations.The platform is designed to overcome limitations of current treatment limitations by delivering a highly selective protein degrader to tumor cells and avoiding healthy cells, according to Johnson & Johnson."KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years," said John Reed, executive vice president for innovative medicine and research and development at J&J."We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors," Reed said.The acquisition of Firefly Bio is the latest move by Johnson & Johnson to expand its oncology pipeline and advance its aim to develop targeted medicines for the most prevalent and hard-to-treat solid cancer tumors.In December, Johnson & Johnson acquired Halda Therapeutics for $3.05 billion to expand its portfolio of therapies for solid tumors, including prostate cancer, while in March 2024 it acquired Ambrx Biopharma, whose portfolio comprised of products targeting multiple types of cancers, for $2 billion.The deal for Firefly Bio is expected to close later this year, subject to regulatory approvals.Shares of Johnson & Johnson, up about 12% so far this year, were off by about 0.2% in Monday trading.Price: $231.91, Change: $-0.86, Percent Change: -0.37%

$JNJ
Wire

Johnson & Johnson Says Lung Cancer Study on Rybrevant Plus Lazcluze Suggests Potential for More Durable Disease Control

Johnson & Johnson (JNJ) said Friday that updated Phase 1/1b CHRYSALIS-2 data showed Rybrevant plus Lazcluze achieved a median overall survival of 41 months in patients with advanced non-small cell lung cancer with atypical epidermal growth factor receptor mutations.The company said the results add to the evidence showing potential of this combination to deliver durable survival outcomes in both common and atypical EGFR-mutated advanced NSCLC in the first-line setting.The company said the combination previously demonstrated a 57% objective response rate and showed consistent clinical activity across atypical EGFR mutation subgroups.Price: $224.71, Change: $-6.09, Percent Change: -2.64%

$JNJ
Wire

Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning trading Monday, as Wall Street monitored oil prices and US Treasury yields amid the ongoing conflict in the Middle East.In company news, NextEra Energy (NEE) and Dominion Energy (D) said Monday they have entered into a definitive agreement to combine in an all-stock deal. Under the terms of the transaction, Dominion shareholders will receive a fixed exchange ratio of 0.8138 shares of NextEra for each Dominion share they own at the close of the deal, which is expected in the next 12 to 18 months. NextEra shareholders will own about 74.5% of the combined company, while Dominion shareholders will own the remaining 25.5%. NextEra shares were down 5.5% around midday, while Dominion shares were up 9.6%.The US Supreme Court on Monday denied writ of certiorari petitions by six big pharmaceutical companies seeking to challenge the legality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol-Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court. Shares of AstraZeneca, Novartis, Johnson & Johnson and Bristol-Myers were up 1.1%, 0.8%, 0.4% and 0.5%, respectively, while Novo Nordisk was down 1%.Berkshire Hathaway (BRK.A, BRK.B) disclosed Friday in a regulatory filing that it sold all of its stake in UnitedHealth Group (UNH). Separately, a New York state court judge on Monday prohibited prosecutors from using some evidence found in the backpack of Luigi Mangione, who is standing trial for the murder of UnitedHealth Group's UnitedHealthcare CEO Brian Thompson, CNBC reported. UnitedHealth shares were down 1.5%, while Berkshire's class A and class B shares were up 0.2% and 0.1%, respectively.Citigroup (C) and BlackRock's (BLK) HPS Investment Partners are launching a 15 billion euro ($17.48 billion) private capital program to expand access to private financing for corporate and sponsor-owned borrowers in the Europe, the Middle East and Africa region, the companies said Monday. Citigroup shares were down 0.2%, while BlackRock shares were up 0.5%.Price: $88.24, Change: $-5.13, Percent Change: -5.49%

$AZN$BLK$BMY$BRK.A$BRK.B$C$D$JNJ$NEE$NVO$NVS$UNH
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from.Price: $183.25, Change: $+1.67, Percent Change: +0.92%

$AZN$BMY$JNJ$NVO$NVS
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

$AZN$BMY$JNJ$NVO$NVS
Research

Leerink Partners Upgrades Johnson & Johnson to Outperform From Market Perform, Adjusts PT to $265 From $252

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $261, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$JNJ
Wire

Johnson & Johnson Launches Shockwave C2 Aero Coronary IVL Catheter

Johnson & Johnson (JNJ) said Tuesday it has launched its Shockwave C2 Aero Coronary IVL Catheter, expanding its intravascular lithotripsy portfolio for the treatment of calcified coronary artery disease.The next-generation catheter is designed to enhance deliverability, lesion crossing, and balloon repositioning, the company said.Shockwave C2 Aero is now available in the US and Japan and will be available in Europe and Canada in the coming months, it said.Price: $223.37, Change: $+1.94, Percent Change: +0.87%

$JNJ
Wire

AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says

AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are "overdone," BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers "one of the best" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.Shares of AbbVie were up more than 4% in Thursday trading.Price: $212.77, Change: $+8.88, Percent Change: +4.36%

$ABBV$JNJ
Wire

Johnson & Johnson Says Imaavy Shows Sustained Disease Control in Myasthenia Gravis

Johnson & Johnson (JNJ) said Wednesday that new phase 3 data demonstrates that Imaavy provides sustained disease control over more than two years in patients with generalized myasthenia gravis.The phase 3 study and its open-label extension showed sustained improvements in symptoms and quality of life over 120 weeks, along with durable reductions in disease-driving antibodies, with many patients achieving and maintaining minimal symptom expression, the company said.Johnson & Johnson also said its EPIC study, the first head-to-head study of Imaavy versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participantsPrice: $226.58, Change: $+0.42, Percent Change: +0.19%

$JNJ
Wire

Argus Raises Price Target on Johnson & Johnson to $275 From $240

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $256.39, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $237.10, Change: $-3.00, Percent Change: -1.25%

$JNJ
Wire

Update: BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating

(Updated to include BofA's commentary)BofA Securities raised its price target on Johnson & Johnson (JNJ) to $254 from $253, while maintaining its Neutral rating after the company's reported better-than-expected Q1 results.Given the results, the brokerage modestly raised its 2026 forecasts mainly for Tremfya (immunology). But, as there were no thesis-changing updates, with the company providing above-peer top-line growth and favorable LOE profile, which is already reflected in its premium multiple, the brokerage reiterated its Neutral rating on balanced risk/reward.Johnson & Johnson has an average rating of overweight and mean price target of $256.39, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $237.77, Change: $-2.33, Percent Change: -0.97%

$JNJ
Wire

Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says

Johnson & Johnson (JNJ) reported above-peer top-line growth in Q1 and a limited loss-of-exclusivity exposure, but that is already reflected in the company's premium multiple, BofA Securities said in a client note Wednesday.In its Q1 results, Johnson & Johnson did not provide any material research and development pipeline updates, with the investor call focusing on the Icotyde plaque psoriasis drug launch and reasons for perceived "softness" in MedTech, the BofA analysts said."Overall, 1Q offered nothing thesis changing," the analysts said.BofA said that the company's Tremfya drug has solidified its "number two" position in the drug target category, aided by subcutaneous Crohn's induction, with that benefit expected to neutralize when competitor AbbVie (ABBV) launches subcutaneous Skyrizi in 2027.The analysts updated their Tremfya peak sales estimate to $13 billion from $11 billion.BofA retained a neutral rating on the stock and increased its price target to $254 from $253.Price: $238.42, Change: $-1.68, Percent Change: -0.70%

$ABBV$JNJ
Wire

BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating

Johnson & Johnson (JNJ) has an average rating of overweight and mean price target of $256.39, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $238.18, Change: $-1.92, Percent Change: -0.80%

$JNJ
Wire

Johnson & Johnson Q1 Reinforces Growth Outlook on New Product Cycle, Morgan Stanley Says

Johnson & Johnson's (JNJ) Q1 results reinforced Morgan Stanley's confidence in the company's growth trajectory, driven by its new product cycle, including Icotyde.The company reaffirmed its long-term outlook and sees a path to double-digit revenue growth by 2030. Johnson & Johnson also highlighted key Pharma growth drivers, including Icotyde, Rybrevant and Inlexzo. It further pointed to cardiovascular launches and the Orthopedics separation as tailwinds in MedTech.Johnson & Johnson posted a Q1 beat and slightly lifted 2026 revenue guidance to $100.3 billion to $101.3 billion. This compares with Morgan Stanley's estimate of $101.1 billion and Street estimate of $100.6 billion. New adjusted EPS guidance was $11.45 to $11.65, versus Morgan Stanley's estimate of $11.82 and consensus of $11.56.The company expects heavier investment in H1, with stronger earnings growth in H2 as new product launches scale, according to the note Tuesday.Upcoming catalysts include additional readouts for Icotyde across plaque psoriasis and psoriatic arthritis. The company also expects data from the phase 2 Duet trials in ulcerative colitis and Crohn's disease. Phase 3 readouts of Milvexian in atrial fibrillation and secondary stroke prevention are also expected.Morgan Stanley maintained an overweight rating on Johnson & Johnson and raised its price target to $283 from $267.Price: $238.95, Change: $-1.15, Percent Change: -0.48%

$JNJ

Showing 1-20 of 33

JNJ News | FINWIRES